Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib Combined With PD-1 Antibody in Unresectable High-grade Chondrosarcoma
NCT05193188Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Feb 2023
- Primary completion
- Mar 2025
- Countries
- 1
01
Overview
Phase 2, open-label trial in chondrosarcoma (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: 6-month Progression-Free Survival Rate. Started Feb 2023; status: recruiting.
02
Conditions
chondrosarcoma
Beyond the preview
Go deeper on NCT05193188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05193188.